Matthew Macaluso, DO

Department of Psychiatry, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama

  • 13Articles
  • 55.5KReads
  • 2010–2026Active
  • 89Collaborators
  • 236Citations

About

Matthew Macaluso, DO is affiliated with Department of Psychiatry, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama. Matthew Macaluso has authored or co-authored 13 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2010 and 2026. Their work focuses on Depression (MDD), Psychiatry, Suicide, Child and Adolescent Psychiatry, and COVID.

Publications

JCP
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

May 4, 2026

In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
, , , et al
PCC
Brief Report

ECHO Model to Improve Depression Outcomes During COVID-19

January 13, 2022

Extension for Community Health Outcomes (ECHO) Depression was designed to improve health care delivery for depressed patients in Alabama, which is particularly important during the COVID-19 pandemic. Read on...
, ,
JCP
Original Research

Response to Esketamine After Initial Nonresponse

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

Utility of Combinatorial Pharmacogenomics in Depression

October 31, 2019

This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...
, , , et al
PCC
Article

Yellow Ribbon Suicide Prevention Program Evaluation

June 30, 2016

Yellow Ribbon is a gatekeeper-type suicide prevention program that is widely used in public schools. However, data on its effectiveness are limited. Thus, the authors of this Continuing Medical...
, , , et al
PCC
Article

Wernicke's Encephalopathy: Diagnosis and Treatment

May 21, 2015

Permanent brain damage, long-term institutionalization, and death can result from undiagnosed and untreated Wernicke's encephalopathy. Too many cases are not diagnosed until autopsy. Do you know which patients are...
, , , et al
PCC
Letter to the Editor

The First Published Case Report of an Adult Woman Who Developed Suicidal Ideation as an Adverse Event Related to Methylphenidate Use

March 26, 2015

,
PCC
Article

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example

March 19, 2015

How do you avoid drug-drug interactions in your patients who are taking multiple medications? This article explains the process for assessing the risk of a drug causing or being...
, ,
PCC
Letter to the Editor

Secondary Psychosis 3 Months Prior to the Overt Symptoms of Multiple Myeloma: A Case Report

April 15, 2014

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe